Promising Glioma Results

Forma Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced recently that the company’s investigational IDH1m inhibitor, olutasidenib, demonstrated a preliminary disease control rate of 50% in heavily pre-treated patients with predominantly enhancing, recurrent mIDH1…   Read More

COVID-19 CD8+ Analysis.

Current clinical trials are underway to evaluate the most appropriate medical interventions that will prevent and/or treat the severe hallmarks of COVID-19, namely multi-organ failure of the lungs, heart, kidneys and other organs, while work continues toward development of effective…   Read More

Covid-19 Clinical Trial Analysis

Imaging Endpoints’ COVID-19 analysis supports the detection and standardized recording of the clinical and radiological disease features consistent with the course of COVID-19 infection as well as the relevant epidemiological disease history. This data-driven approach offers a systematic means to…   Read More